Skip to main content
. Author manuscript; available in PMC: 2023 Aug 8.
Published in final edited form as: Cancer Cell. 2022 Aug 8;40(8):865–878.e6. doi: 10.1016/j.ccell.2022.07.004

Figure 7: Tumor Infiltrating Lymphocyte Quantification in Patient Risk Groups.

Figure 7:

TIL quantification in high attention regions of predicted low- (BLCA n=90, BRCA n=220, COADREAD n=74, HNSC n=96, KIRC n=80, KIRP n=36, LGG n=133, LIHC n=85, LUAD n=105, LUSC n=97, PAAD n=40, SKCM n=29, STAD n=53, UCEC=104) and high-risk patient cases (BLCA n=93, BRCA n=223, COADREAD n=80, HNSC n=103, KIRC n=80, KIRP n=63, LGG n=68, LIHC n=84, LUAD n=89, LUSC n=103, PAAD n=40, SKCM n=55, STAD n=78, UCEC=125) across 14 cancer types. For each patient, the top 1% of scored high attention regions (512 × 512 40× image patches) were segmented and analyzed for tumor and immune cell presence. Image patches with high tumor-immune co-localization were indicated as positive for TIL presence (and negative otherwise). Across all patients, the fraction of high attention patches containing TIL presence was computed and visualized in the box plots. A two-sample t-test was computed for each cancer type to test the if the means of the TIL fraction distributions of low- and high-risk patients had a statistically significant difference (with * marked if P-Value < 0.05).